Drugmaker Dr Reddy's Laboratories said on Monday phase III clinical trial for its anti-diabetic molecule balaglitazone, being conducted by Danish firm Rheoscience, had achieved the set parameters.
"These results offer the opportunity for a constructive series of dialogues with both potential partners as well as regulatory agencies," Dr Reddy's chief executive GV Reddy said in a statement.
Comments